Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors," commented Dr. Barry Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), increa
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 The following is a Statement ... at Drugfree.org :   Last Friday, ... was halting the sale of prescription drug paraphernalia products. The ... that from time to time there may be individual items ... As a result of this misinterpretation we are electing to ...
(Date:6/17/2013)... YORK , June 17, 2013  A little known ... come under scrutiny by the U.S. Supreme Court – and ... the issue could not have come at a better time ... that result from the Rx industry tactic are all too ... survey of 50+ New Yorkers, state residents are in a ...
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- United Medical ... for consumers, including gastric bypass and lap band ... in order to effectively contact as many physicians as ... in staff is all part of the company,s overall ... assist patients with both good and bad credit to ...
Breaking Medicine Technology:A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services 2United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services 3
(Date:6/17/2013)... (PRWEB) June 17, 2013 "Do you think ... are texting, emailing or using your phone even with a ... warns it is just as dangerous as not using a ... those of you using Facebook, texting, emailing etc." ... and alters their reflexes that distract the brain, according to ...
(Date:6/17/2013)... NY (PRWEB) June 17, 2013 ... & Murphy, LLP are pleased to announce that ... and David L. Scher ( http://www.blockotoole.com/Attorneys/David-L-Scher.shtml ) will ... Z100 (100.3 FM) this Sunday, June 23, 2013 ... will be guests on Kevin Burke's "Get Active" ...
(Date:6/17/2013)... Los Angeles (PRWEB) June 17, 2013 According ... Confusing Sunscreen Questions Answered,” as more and more information surfaces ... , sunscreen should become a vital part of one’s ... premature aging and cancer (Go to goo.gl/qTKZQ). , “I ... apply sunscreen,” says Dr. Simon Ourian, Medical Director of Epione ...
(Date:6/17/2013)... June 17, 2013 As da Vinci ... around the country, Bernstein Liebhard LLP notes that a recent ... detailed some of the disturbing robotic surgery complications alleged to ... Among other things, the June 14th broadcast revealed that the ... 200 reports of da Vinci patients who suffered burns, cuts ...
(Date:6/17/2013)... San Antonio Eye Center PA has been growing a lot recently. ... a new portion of the office, the optical shop. Their loyal ... years, and SA Eye Center has delivered. , The new ... providing patients with everything they need in regards to eye care, ... the largest SA Eye Center in the city. The shop ...
Breaking Medicine News(10 mins):Health News:Dr. Bonnie Weil Warns Hands Free is Not a Life Saver, It Can Be Just as Much of a Distraction 2Health News:Injury Attorneys Block O'Toole & Murphy, LLP to Appear on Z100 Radio Show This Sunday to Discuss Their Support of St. Jude Children's Research Hospital 2Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 3Health News:San Antonio Eye Center PA Opens New Optical Shop 2
... CHARLOTTE, N.C., Oct. 15 After the success ... Gala, Dienst Custom Homes and the,Make-A-Wish Foundation(R) of ... over 40 wishes to date for Charlotte-area children ... 21, 2007,at a Dienst custom home in the ...
... New Coalition Web Site Launched to Provide Educational Resources to ... of Influenza, ... Importance of Annual Immunization, BETHESDA, Md., Oct. 15 ... http://www.PreventChildhoodInfluenza.org, to support its newly issued report that,calls for ...
... Report finds a doubling of the rate of decline over ... rates from cancer are dropping more quickly across the United ... against a leading killer. , According to a new report, ... 2002 through 2004 -- almost double the 1.1 percent annual ...
... 2007 Post-hoc and other analyses of secondary endpoints ... plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis ... in patients with mild to moderate ulcerative colitis. These ... open-label 12-14 month extension study, are being presented this ...
... 15 Facet Solutions, Inc. announced,today that it ... cohort of,patients to receive its Anatomic Facet Replacement ... one year include a significant,decline in leg and ... complications. Additionally, the first patient in the,AFRS(TM) study ...
... Patients with obstructive sleep apnea (OSA) who also suffer ... positive airway pressure (CPAP) relieves them of symptoms of ... 15 issue of the Journal of Clinical Sleep Medicine ... Center at Universitys Community Hospital in Tampa, Fla., surveyed ...
Cached Medicine News:Health News:Dienst Custom Homes Grants Over 40 'Wishes' in Three Years 2Health News:Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates 2Health News:Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates 3Health News:Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates 4Health News:Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates 5Health News:U.S. Cancer Death Rate Continues to Fall 2Health News:U.S. Cancer Death Rate Continues to Fall 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:Facet Solution's AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: